127.96
-0.25 (-0.19%)
| Previous Close | 128.21 |
| Open | 128.18 |
| Volume | 4,731,774 |
| Avg. Volume (3M) | 2,531,034 |
| Market Cap | 8,274,674,176 |
| Price / Sales | 14.46 |
| Price / Book | 24.15 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -27.70% |
| Operating Margin (TTM) | -27.50% |
| Diluted EPS (TTM) | -2.51 |
| Quarterly Revenue Growth (YOY) | 55.50% |
| Quarterly Earnings Growth (YOY) | -99.40% |
| Total Debt/Equity (MRQ) | 208.50% |
| Current Ratio (MRQ) | 2.80 |
| Operating Cash Flow (TTM) | -145.55 M |
| Levered Free Cash Flow (TTM) | -20.78 M |
| Return on Assets (TTM) | -9.75% |
| Return on Equity (TTM) | -47.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Blueprint Medicines Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.30 |
|
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.86% |
| % Held by Institutions | 109.40% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avoro Capital Advisors Llc | 31 Mar 2025 | 3,850,000 |
| William Blair Investment Management, Llc | 31 Mar 2025 | 1,429,668 |
| T. Rowe Price Investment Management, Inc. | 31 Mar 2025 | 1,302,810 |
| Rock Springs Capital Management Lp | 31 Mar 2025 | 1,007,569 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 135.00 (Stephens & Co., 5.50%) | Hold |
| 135.00 (Scotiabank, 5.50%) | Hold | |
| 135.00 (HC Wainwright & Co., 5.50%) | Buy | |
| 135.00 (Jefferies, 5.50%) | Buy | |
| Median | 129.50 (1.20%) | |
| Low | 129.00 (UBS, 0.81%) | Hold |
| 129.00 (Morgan Stanley, 0.81%) | Hold | |
| 129.00 (Citigroup, 0.81%) | Hold | |
| 129.00 (JP Morgan, 0.81%) | Hold | |
| 129.00 (Wedbush, 0.81%) | Hold | |
| Average | 131.50 (2.77%) | |
| Total | 2 Buy, 8 Hold | |
| Avg. Price @ Call | 121.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 05 Jun 2025 | 129.00 (0.81%) | Hold | 127.90 |
| 20 Mar 2025 | 100.00 (-21.85%) | Hold | 88.47 | |
| UBS | 05 Jun 2025 | 129.00 (0.81%) | Hold | 127.90 |
| Citigroup | 04 Jun 2025 | 129.00 (0.81%) | Hold | 128.10 |
| Stephens & Co. | 03 Jun 2025 | 135.00 (5.50%) | Hold | 127.60 |
| JP Morgan | 02 Jun 2025 | 129.00 (0.81%) | Hold | 127.79 |
| Needham | 02 Jun 2025 | 130.00 (1.59%) | Hold | 127.79 |
| 28 Apr 2025 | 130.00 (1.59%) | Buy | 88.51 | |
| Scotiabank | 02 Jun 2025 | 135.00 (5.50%) | Hold | 127.79 |
| Wedbush | 02 Jun 2025 | 129.00 (0.81%) | Hold | 127.79 |
| 16 Apr 2025 | 128.00 (0.03%) | Buy | 82.11 | |
| HC Wainwright & Co. | 02 May 2025 | 135.00 (5.50%) | Buy | 104.64 |
| Jefferies | 17 Mar 2025 | 135.00 (5.50%) | Buy | 92.14 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CARTER PERCY H. | - | 127.60 | -2,659 | -339,288 |
| Aggregate Net Quantity | -2,659 | |||
| Aggregate Net Value ($) | -339,288 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 127.60 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CARTER PERCY H. | Officer | 03 Jun 2025 | Sell (-) | 2,659 | 127.60 | 339,288 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |